Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements - Novo Nordisk - Additional Information (Details)

v3.6.0.2
Collaborative, Licensing and Other Arrangements - Novo Nordisk - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Performance deliverable period for license and transfer of technology and knowhow   60 days  
Upfront payment recognized as revenue     $ 5,000,000
Novo Nordisk [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Upfront payment received $ 5,000,000    
Agreement termination notice period   90 days  
Collaborative Arrangement [Member] | Novo Nordisk [Member]      
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]      
Upfront payment received     $ 5,000,000
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 290,000,000  
Milestone received under the collaboration agreement   $ 0